An observational study in Post Thrombotic Syndrome, Venous Thromboembolism and Cardiovascular Diseases, sponsored by Association des Médecins Vasculaires Hospitaliers. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-23.
Sponsored by Association des Médecins Vasculaires Hospitaliers · Observational
Post-thrombotic syndrome (PTS) is a frequent and burdensome complication of deep-vein thrombosis (DVT). In the absence of curative treatment of established PTS, its management is based on the prevention of its occurrence thanks to anticoagulants and compression stockings.
So far, predictors of disabling PTS are unknown precluding from optimally selecting patients for invasive (early thrombus removal) or innovative/expensive treatments. In addition, little is known on the incidence of PTS in the very long-term.
Objectives: To assess, 12 years after a symptomatic venous thromboembolic (VTE) event, Primary objective: incidence and severity of PTS after a lower limb DVT.
Main Secondary objectives:
All patients with a DVT, an isolated PE and a random selection of controls (VTE - patients without any history of VTE after the 3 years of follow-up) will first benefit from a phone-PTS assessment. Those patients presenting at least a mild venous insufficiency and a selection of controls will undergo a clinical follow-up visit with clinical and Compleat Ultra Sound (CUS) assessment of PTS/venous insufficiency and an assessment of quality of life.
Perspectives: Improving our knowledge of PTS' incidence and predictors and of the impact of usual treatment. Better selecting patients eligible for invasive/innovative/expensive preventative procedures.
Post thrombotic syndrome (PTS) refers to chronic manifestations of venous insufficiency following a deep vein thrombosis (DVT). It is the most frequent complication of DVT, which affects up to 40% of patients after a proximal DVT (popliteal veins and above).
Though not lethal, PTS is burdensome and severly impacts patient's quality of life (QOL). In addition after a DVT, PTS was found to be an important predictor of total and medical costs. Thus PTS is not just a cosmetic problem and constitutes a real public health concern in the field of VTE. However, so far, many epidemiologic and therapeutic issues remain unresolved.
On an epidemiologic point of view, incidence of PTS in the long term (i.e. after 5 years) is largely unknown. In addition, there is no available reliable data on the risk of PTS after isolated distal DVT (i.e. infrapopliteal DVT without pulmonary embolism (PE), >50% of all lower limb DVT) or isolated PE. At last, risk and independent predictors of the most severe disabling forms of PTS (particularly venous claudication and venous ulcers) need to be assessed (absence or old and outdated data).
On a therapeutic point of view, so far there is no curative treatment of established PTS. The cornerstone of PTS' treatment lies on its prevention via an optimal anticoagulation therapy, the use of compression stockings (the effectiveness of which was recently questioned by the SOX RCT trial) and sometimes thrombolysis for cases of very proximal DVT without bleeding risk. Impact in the very long term of usual DVT treatment on PTS natural history, prescribed in routine clinical practice in a real life setting, has never been assessed. Furthermore, absence of identified independent predictors of disabling PTS constitutes an important break to the use and to assess the full effectiveness of invasive therapies.
In this perspective, the investigators aim performing a very long term follow-up (12 years) of the already constituted OPTIMEV cohort in order to try to answer most of the above-mentioned epidemiologic and therapeutic unresolved issues.
Objectives Primary objective: To assess incidence (from baseline till up to 12 years) and severity of PTS, 12 years after a lower limb DVT, calculated with the clinical Villalta score.
Secondary objectives: To assess in the very long term (12 years)
Methods Cohort study of exposed and unexposed patients nested in the OPTIMEV multicentre observational study (Clinical Trials NCT00670540) Constitution of the OPTIMEV cohort: From November 2004 to January 2006, 8256 patients with a suspicion of symptomatic VTE (lower and upper extremity DVT, PE) were enrolled and benefited from objective tests to confirm or rule out the suspicion of VTE. This included a bilateral whole leg compression CUS for all cases of suspicion of DVT; Baseline characteristics including patient's demographics, signs, symptoms \& risk factors for VTE, venous status, results of objective tests and treatments were prospectively collected in an electronic case report form.
Patients with a confirmed VTE and a random selection of controls (patients for whom VTE was ruled out at baseline) were initially followed up by phone by clinical research assistants during 3 years using standardized questionnaires to obtain information on health-related events (death, VTE recurrence, bleeding, arterial cardiovascular events, diagnosis of cancer or of lower limb ulcer, hospitalization and treatments). The general practitioner or the vascular medicine physician was contacted whenever a possible event was reported or when the patient's history seemed potentially unreliable. Medical records were reviewed in case of hospitalization or a new visit to the vascular physician during the follow- up period. All suspected adverse events were adjudicated by the study's expert committee.
At 3 years our rate of lost to follow-up or of patients who declined to continue the study was low (\<3%) For this very long-term follow-up (12 years), patients with VTE and a random selection of patients free from any VTE will be considered.
As per previous follow-up visits, clinical research assistants will contact all eligible patients using the same standardized questionnaires and will assess PTS/venous insufficiency using a validated phone-questionnaire (Villalta score of Utne and Sandset). Patients with a suspicion of disabling PTS/venous insufficiency and a random selection of controls will be referred to a participating vascular medicine physician for a clinical follow-up visit with realization of a PTS assessment (Villalta score and CEAP) and a whole limb CUS exploration of the venous system + Ankle Brachial Index (ABI) measurement). QOL questionnaires will also be filled.
Statistical considerations Statistical analyses will be performed by the Themas team in Grenoble. Based on the results of a pilot-feasibility study (random selection of 100 VTE patients, 15% lost to Follow-Up (FU) and 5% of death), 1000 patients with lower limb DVT or PE at baseline ("exposed" patients) should attend the clinical follow-up visit. This will allow us to estimate, with a precision of plus or menus 3% an incidence of PTS at 12 years of 45% and with a precision of plus or menus 2.5% an incidence of disabling PTS of 20%.
Perspectives This study should improve our knowledge on the long term incidence of PTS according to various presentations of VTE disease, on the impact of routine clinical practice therapeutic management (particularly compression therapies and anticoagulation) on the risk of PTS, and should allow determining independent predictors of disabling PTS. On a clinical practice point of view, this study should assess the benefit of PTS preventative treatment after an isolated DVT or an isolated PE and to better selecting patients eligible for invasive procedures.
4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.
This study's enrollment of 2,475 is above the median of 573 across 1,485 observational studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →This is the only study on the registry with Association des Médecins Vasculaires Hospitaliers as lead sponsor.
Counted across the registry records on this site, refreshed daily.
study of exposed and unexposed patients nested in the propsective OPTIMEV cohort
Exclusion Criteria:
patients with VTE in the OPTIMEV cohort with an Utne and Sandset Villalta phone score \> or = to 5 at the end of the follow-up call AND a random selection of patients free from any VTE after the first 3 years of follow-up in OPTIMEV with an Utne and Sandset Villalta phone score \> or = to 5 at the end of the follow-up call
Other: Villalta phone score > or = to 5 · Other: Villalta phone score < 5
patients with VTE in the OPTIMEV cohort with an Utne and Sandset Villalta phone score \< 5 at the end of the follow-up call AND random selection of patients free from any VTE after the first 3 years of follow-up in OPTIMEV with an Utne and Sandset Villalta phone score \< 5 at the end of the follow-up call
Other: Villalta phone score > or = to 5 · Other: Villalta phone score < 5
Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \> or = 5 will have a visit with clinical and CUS assessments of PTS/ venous insufficiency. All patients will have self administered-questionnaires. For Grenoble Center, the 200 first patients with clinical follow-up will have an Echo-Doppler examination.
Also known as: Clinical Follow-Up Group
Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \< 5, will don't have a clinical follow up. All patients will have self administered-questionnaires.
Also known as: No Clinical Follow-Up Group
disabling PTS
Clinical Villalta score \> or = 10 (moderate or severe PTS) and/or venous claudication (Villalta score assessed during the clinical Follow-Up visit by a vascular medicine physician (signs) and by the patient (symptoms)
Time frame: 12 years
Risk factors of disabling PTS
Risk factors could be evaluated by the data base and the 3 years follow-up of the OPTIMEV cohort and with the follow-up call on medical history of the patient.
Time frame: at inclusion
PTS severity
PTS severity will be assessed with the Villalta scale : 0-4 : no PTS ; 5-9 : mild PTS 10-14 : moderate PTS \> or = to 15 or presence of ulcer: severe PTS
Time frame: at inclusion
Incidence of venous insufficiency
incidence of venous insufficiency will be evaluated with the CEAP classification and the analyse of collected signs and symptoms by the Utne and Sandset Villalta phone score.
Time frame: at inclusion
Global Quality of life
EUROQUOL questionnaire (generic questionnaire)
Time frame: at inclusion
Specific Quality of life
chronic venous disease quality-of-life (CIVIQ) questionnaire
Time frame: at inclusion
Incidence of cancers
number of cancers in the population. Information on cancer occurence will be collected during the phone follow-up
Time frame: at inclusion
Incidence of cardio-vascular events (stroke, myocardial infarction, peripheral arterial disease)
Description with the same definition of the 3-year-follow-up of OPTIMEV. The events will be adjudicated by the study expert committee composed of at the last two doctors, on the basis of medical reports
Time frame: at inclusion
Incidence of deaths
number of deaths in the population. Deaths data will be collected during the phone follow-up visit
Time frame: at inclusion
Incidence of new thromboembolic disease
The event will be adjudicated by the study expert committee composed of at the last two doctors, on the basis of medical reports
Time frame: at inclusion
Attributable risk of DVT in PTS severity
Assessed via the Villalta score by comparing exposed patients and non-exposed patients.
Time frame: at inclusion
Doppler Ultrasound and PTS severity
correlation between Doppler Ultrasound results (deep and/or superficial reflux , lack of recanalization or partial recanalization, parietal sequelae) and different levels of severity of PTS (mild , moderate and severe +/- venous claudication)
Time frame: at inclusion
Incidence of hemorrhage events
The event will be adjudicated by the study expert committee composed of at the last two doctors, on the basis of medical reports
Time frame: at inclusion
Plan to share: No
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.